EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: One-third of doublets occur at five pairs of amino acids

Oncogene

Volumn 27, Issue 31, 2008, Pages 4336-4343

  Chen, Z ^a   Feng, J ^a   Saldivar, J S ^a   Gu, D ^a   Bockholt, A ^a   Sommer, S S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Doublet; EGFR; Lung cancer; Somatic mutation

Indexed keywords

AMINO ACID DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ALLELIC IMBALANCE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; FEMALE; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOMATIC MUTATION;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; AMINO ACIDS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN CONFORMATION; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 47549104067     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.71     Document Type: Article

References (31)

1. Arteaga CL. (2002). Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 29: 3-9.
2. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R et al. (2005). Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37: 1315-1316.
3. Buettner VL, Hill KA, Halangoda A, Sommer SS. (1999). Tandem-based mutations occur in mouse liver and adipose tissue preferentially as G:C to T:A transversions and accumulate with age. Environ Mol Mutagen 33: 320-324.
4. Buettner VL, Hill KA, Scaringe WA, Sommer SS. (2000). Evidence that proximal multiple mutations in Big Blue transgenic mice are dependent events. Mutat Res 452: 219-229.
5. Chen YR, Fu YN, Lin CH, Yang ST, Hu SF, Chen YT et al. (2006). Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 25: 1205-1215.
6. Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G et al. (2005). Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65: 7591-7595.
7. Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ et al. (2007). Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res 67: 7319-7326.
8. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G et al. (2007). Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
9. Gu D, Scaringe WA, Li K, Saldivar JS, Hill KA, Chen Z et al. (2007). Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. Hum Mutat 28: 760-770.
10. Hill KA, Wang J, Farwell KD, Sommer SS. (2003). Spontaneous tandem-base mutations (TBM) show dramatic tissue, age, pattern and spectrum specificity. Mutat Res 534: 173-186.
11. Hill KA, Wang J, Farwell KD, Scaringe WA, Sommer SS. (2004). Spontaneous multiple mutations show both proximal spacing consistent with chronocoordinate events and alterations with p53-deficiency. Mutat Res 554: 223-240.
12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
13. Ma ES, Wong CL, Siu D, Chan WK. (2007). Amplification, mutation and loss of heterozygosity of the EGFR gene in metastatic lung cancer. Int J Cancer 120: 1828-1831.
14. Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA et al. (2007). Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 67: 2325-2330.
15. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
16. Regales L, Balak MN, Gong Y, Politi K, Sawai A, Le C et al. (2007). Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS ONE 2: e810.
17. Saldivar JS, Chen Z, Sommer SS. (2006). Current Protocols in Human Genetics In: Haines JL, Korf BR, Morton CC, Seidman JG, Smith DR (eds). John Wiley & Sons, Inc., Hoboken, NJ, USA, Unit 10.9, pp 1-14.
18. Shigematsu H, Gazdar AF. (2005a). Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118: 257-262.
19. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II et al. (2005b). Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346.
20. Shintani S, Kiyota A, Mihara M, Sumida T, Kayahara H, Nakashiro K et al. (2003). Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Am J Clin Oncol 26: e150-e156.
21. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
22. Sommer SS, Cohen JE. (1980). The size distributions of proteins, mRNA, and nascent transcripts. J Mol Evol 15: 37-57.
23. Sommer SS, Groszbach AR, Bottema CDK. (1992). PCR amplification of specific alleles (PASA) is a general method for rapidly detecting known single-base changes. BioTechniques 12: 82-87.
24. Sordella R, Bell DW, Haber DA, Settleman J. (2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167.
25. Strauss BS. (1997). Silent and multiple mutations in p53 and the question of the hypermutability of tumors. Carcinogenesis 18: 1445-1452.
26. Strauss BS. (2000). Role in tumorigenesis of silent mutations in the TP53 gene. Mutat Res 457: 93-104.
27. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U et al. (2005). Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 6829-6837.
28. Tam IY, Chung LP, Suen WS, Wang E, Wong MC, Ho KK et al. (2006). Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 12: 1647-1653.
29. Vikis H, Sato M, James M, Wang D, Wang Y, Wang M et al. (2007). EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res 67: 4665-4670.
30. Yokoyama T, Kondo M, Goto Y, Fukui T, Yoshioka H, Yokoi K et al. (2006). EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Sci 97: 753-759.
31. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M et al. (2007). Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11: 217-227.